Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

AB Science (AB) Eur0.01

Sell:€5.05 Buy:€5.20 Change: €0.21 (3.95%)
Market closed |  Prices as at close on 6 December 2019 | Switch to live prices |
Sell:€5.05
Buy:€5.20
Change: €0.21 (3.95%)
Market closed |  Prices as at close on 6 December 2019 | Switch to live prices |
Sell:€5.05
Buy:€5.20
Change: €0.21 (3.95%)
Market closed |  Prices as at close on 6 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The Company is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.

Contact details

Address:
3 avenue George V
PARIS
75008
France
Telephone:
+33 (1) 47200014
Website:
www.ab-science.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AB
ISIN:
FR0010557264
Market cap:
€230.95 million
Shares in issue:
41.60 million
Sector:
Pharmaceuticals
Exchange:
Euronext Paris
Country:
France
Currency:
Euro
Indices:
n/a

Key personnel

  • Alain Moussy
    Chairman of the Board, Chief Executive Officer
  • Denis Gicquel
    Deputy Chief Executive Officer
  • Laurent Guy
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.